Hyglos can use recombinant factor C technology protected by Lonza patents to produce own products
Lonza Walkersville in the US and Hyglos, a German biotech company, have signed an agreement that allows Hyglos to use recombinant factor C technology protected by Lonza’s patents to produce Hyglos’ own endotoxin products. The agreement also includes the dismissal of the lawsuit Lonza previously filed against Hyglos.
The financial terms of the settlement have not been revealed.
“Thanks to this agreement an important door has opened for a new era in endotoxin detection,” said Wolfgang Mutter, General Manager of Hyglos.
“We are convinced that Hyglos’ innovative assays, entirely based on recombinant molecules, are addressing important needs of endotoxin testing laboratories worldwide.”
Teun Van der Heide, Head of Lonza Bioscience, added: “We are very glad to have reached this agreement with Hyglos. Endotoxin detection using recombinant factor C instead of Limulus amoebocyte lysates has recently been acknowledged by the FDA as an alternative method. We believe that this sustainable animal-free alternative will be the future of endotoxin detection.”